-
2 weeks ago | 
ajmc.com | Kyle Munz |Ajai Chari
While much attention has been given to the merits and potential of triple and quadruple therapy in multiple myeloma, Ajai Chari, MD, University of California, San Francisco, emphasized how it is not just the number of agents that matters in successful treatments, but how they are used. Dosing intensity, frequency, and real-world feasibility often carry more weight than the theoretical power of a multi-drug regimen.
-
2 weeks ago | 
ajmc.com | Kyle Munz |Ajai Chari
For many patients with multiple myeloma, how a regimen is dosed may matter more than how many agents are included, according to Ajai Chari, MD, of the University of California San Francisco. As the field explores novel triplet and quadruplet combinations, Chari emphasized the need for more personalized treatment approaches—not just to advance research, but to improve outcomes for older, frail, and high-risk populations.
-
1 month ago | 
ajmc.com | Kyle Munz |Ajai Chari
The future of multiple myeloma treatment is bright, but it hinges on overcoming barriers to access and affordability, argued Ajai Chari, MD, University of California San Francisco, in an interview with The American Journal of Managed Care®. As he previously discussed, chimeric antigen receptor (CAR) T-cell and bispecific therapies have fundamentally altered patient outcomes and quality of life for patients with multiple myeloma (MM).
-
1 month ago | 
ajmc.com | Kyle Munz |Ajai Chari
Previously, Ajai Chari, MD, University of California San Francisco (UCSF), spoke to the operational challenges of integrating chimeric antigen receptor T-cell (CAR T) and bispecific therapies into clinical practice. Notably, he emphasized the need to educate providers to manage potential adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
-
1 month ago | 
ajmc.com | Kyle Munz |Ajai Chari
In his previous interview, Ajai Chari, MD, University of California San Francisco, discussed the primary operational challenges health care systems face when they aim to implement chimeric antigen receptor (CAR) T-cell therapies into their practice. As CAR T-cell therapy has proved a valuable treatment option for patients with multiple myeloma, so too has the advent of bispecific therapies.
-
1 month ago | 
ajmc.com | Kyle Munz |Ajai Chari
The advent of chimeric antigen receptor (CAR) T-cell therapies has brought numerous advantages to the multiple myeloma treatment landscape; however, implementing these therapies into clinical practice comes with its own challenges. In this interview with The American Journal of Managed Care®, Ajai Chari, MD, University of California San Francisco, points specifically to operational delays that extend “brain-to-vein” time and hamper efforts to provide these therapies on the community level.
-
Nov 26, 2024 | 
cancernetwork.com | Morie A Gertz |Ajai Chari
November 26, 2024By Panelists discuss how the CEPHEUS trial’s demonstration of improved progression-free survival with daratumumab-VRd versus VRd alone in transplant not-preferred NDMM provides compelling evidence for quadruplet therapy in this setting, though considerations of cost, toxicity management, and patient selection remain important factors in implementation. Video content above is prompted by the following:What are your impressions of the CEPHEUS data that was recently presented?
-
Nov 19, 2024 | 
cancernetwork.com | Morie A Gertz |Ajai Chari
November 19, 2024By Panelists discuss how recent clinical trials have demonstrated improved outcomes with antibody-containing regimens and biomarker-driven approaches in patients with transplant not-preferred newly diagnosed multiple myeloma (NDMM). Video content above is prompted by the following:What are your perspectives on the data from the MAIA, BENEFIT, and IMROZ trials? How does the data impact frontline treatment for patients with NDMM who are not transplant-preferred?
-
Nov 12, 2024 | 
cancernetwork.com | Morie A Gertz |Ajai Chari
November 12, 2024By Panelists discuss how the decision between quadruplet versus triplet therapy depends on multiple factors, including cytogenetic risk status, insurance coverage/drug access, patient fitness to tolerate additional toxicity, and the strength of evidence supporting improved outcomes with 4-drug combinations.
-
Oct 29, 2024 | 
cancernetwork.com | Morie A Gertz |Ajai Chari
Panelists discuss how VRd (bortezomib, lenalidomide, dexamethasone) remains the standard frontline regimen for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, though some now consider adding daratumumab (dara-VRd) in high-risk cases. Video content above is prompted by the following:• What is your current approach to frontline therapy for transplant-preferred NDMM?
